However, one study using the pharmacovigilance information captured in the Eudra-Vigilance and Food and Drug Administration databases showed that, regarding specific CV disorders, the LHRH antagonist degarelix presented lower risks of hypertension (pooled relative risk [PRR] 0.60; 95% CI 0.37–0.98; P = 0.04) and MI (PRR 0.05; 95% CI 0.01–0.39; P < 0.01) compared with LHRH agonists (67). The gene discussed is GNRH1; the disease is hypertensive disorder.